Effects of atypical antipsychotics on weight and serum lipid levels

Journal of Clinical Psychiatry

Volumn 62, Issue SUPPL. 27, 2001, Pages 27-34

  Meyer, Jonathan M ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; LITHIUM; NEUROLEPTIC AGENT; TRIACYLGLYCEROL; VALPROIC ACID;

BODY WEIGHT; CARDIOVASCULAR RISK; DIET; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; METABOLIC DISORDER; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SMOKING HABIT; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BODY WEIGHT; DRUG MONITORING; HUMANS; HYPERTRIGLYCERIDEMIA; LIPIDS; OBESITY; RISK FACTORS; SCHIZOPHRENIA;

EID: 0035684803     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Economic costs of obesity and inactivity
2. Mortality in a cohort of patients with schizophrenia: A record linkage study
3. Excess mortality of mental disorder
4. The association of medical comorbidity in schizophrenia with poor physical and mental health
5. Mortality and causes of death in schizophrenia in Stockholm county, Sweden
6. The distribution of body mass index among individuals with and without schizophrenia
7. The disease burden associated with overweight and obesity
8. Compliance with antipsychotic drug treatment: Influence of side effects
9. Physical and psychological consequences of weight gain
10. Adherence to antipsychotic medications
11. Obesity as a risk factor for antipsychotic noncompliance
12. Weight gain: Side effect of atypical neuroleptics?
13. Weight gain associated with antipsychotic drugs
14. Novel antipsychotics: Comparison of weight gain liabilities
15. Antipsychotic-induced weight gain: A comprehensive research synthesis
16. Weight gain from novel antipsychotic drugs: Need for action
17. Atypical antipsychotics and weight gain: A systematic review
18. Differential effect of clozapine on weight: A controlled study
19. Dosing the antipsychotic medication olanzapine
20. Effect of long-term olanzapine treatment on weight change in schizophrenia
21. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
22. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis Combined results of the North American trials
23. Risperidone in the treatment of schizophrenia: A meta-analysis of randomized controlled trials
24. Risperidone versus haloperidol for prevention of relapse in schizophrenia
25. Weight changes in patients treated with quetiapine
26. Body weight and leptin plasma levels during treatment with antipsychotic drugs
27. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses
28. Clozapine-induced weight gain: Prevalence and clinical relevance
29. Safety of olanzapine
30. A retrospective comparison of lipid, glucose and weight changes at one year between olanzapine and risperidone treated inpatients
31. The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia
32. Risperidone in the treatment of elderly patients with psychotic disorders
33. The efficacy, safety, and tolerability of antipsychotics in the elderly
34. Long-term quetiapine treatment for psychosis in patients with Parkinson's disease who failed treatment with other atypical antipsychotics
35. Obesity: What mental health professionals need to know
36. The relationship of pharmacology to side effects
37. 2C serotonin receptors
38. Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability
39. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene
40. Pharmacological intervention: The antiobesity approach
41. Sibutramine: A novel anti-obesity drug: A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine
42. Serum leptin levels increase rapidly after initiation of clozapine therapy
43. Body weight gain after administration of antipsychotic drugs: Correlation with leptin, insulin and reproductive hormones
44. Effects of the obese gene product on body weight regulation in ob/ob mice
45. Weight-reducing effects of the plasma protein encoded by the obese gene
46. Neuropharmacology of obesity: My receptors made me eat it [Brainstorms]
47. The role of leptin in human obesity and disease: A review of current evidence
48. Recombinant leptin for weight loss in obese and lean adults: A randomized, controlled, doseescalation trial
49. Reinforcement and weight loss in schizophrenics
50. Weight loss with psychiatric residents in a behavioral self control program
51. A study of weight reducing diets in psychiatric in-patients
52. Skills training versus psychosocial occupational therapy for persons with persistent schizophrenia
53. Comparison of efficacy of social skills training for deficit and nondeficit negative symptoms in schizophrenia
54. Nonpharmacologic and pharmacologic management of weight gain
55. What is a reasonable weight loss? patients' expectations and evaluations of obesity treatment outcomes
56. Insulin resistance syndrome: Options for treatment
57. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity
58. Clinical pharmacology of beta 3-adrenoceptors
59. Efficacy and tolerability of sibutramine in obese patients: A dose-ranging study
60. Sibutramine produces doserelated weight loss
61. Abuse liability assessment of sibutramine, a novel weight control agent
62. Sibutramine-associated psychotic episode
63. Role of orlistat in the treatment of obese patients with type 2 diabetes: A 1-year randomized double-blind study
64. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: A 1-y study
65. Orlistat in the treatment of psychopharmacologically induced weight gain
66. Topiramate: A new antiepileptic drug
67. Topiramate as an anti-obesity agent
68. Drug-induced hypertriglyceridemia with and without pancreatitis
69. Hyperlipidemia associated with protease inhibitor therapy
70. Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics
71. Amenorrhea and elevated serum cholesterol produced by a trifluoro-methylated phenothiazine
72. Chlorpromazine in women with chronic schizophrenia: The effect on cholesterol levels and cholesterol-behavior relationships
73. The effect of three butyrophenones on serum cholesterol levels
74. Sterol metabolism: Biochemical differences among the butyrophenones
75. Trifluperidol and cholesterol in man
76. Trifluperidol in chronic male psychiatric patients
77. Further studies on the effect of butyrophenones on cholesterol synthesis in humans
78. Decreased concentration of high density lipoprotein cholesterol in schizophrenic patients treated with phenothiazines
79. Lipids and apolipoproteins in patients treated with major tranquilizers
80. A short survey on untoward effects of fluperlapine
81. Fluperlapine vs haloperidol: A comparison of their neuroendocrinological profiles and the influence on serum lipids
82. Elevated serum triglycerides on clozapine resolve with risperidone
83. Serum trigiyceride levels in patients treated with clozapine
84. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine
85. Olanzapine-induced elevation of plasma triglyceride levels
86. Olanzapine increases weight and serum triglyceride levels
87. Novel antipsychotics and severe hyperlipidemia
88. Atypical antipsychotics and cardiovascular risk in schizophrenic patients
89. Improvements in indices of health status in outpatients with schizophrenia following a switch to ziprasidone from conventional antipsychotics, olanzapine or risperidone
90. The effects of ziprasidone on plasma lipids and glucose
91. Secondary causes of hyperlipidemia
92. Acute pancreatitis following lisinopril rechallenge
93. Hypertriglyceridemia: Changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease
94. Association of lipids and lipoprotein level with total mortality and mortality caused by cardiovascular and cancer diseases (Poland and United States collaborative study on cardiovascular epidemiology)
95. Smoking cessation: Treatment for patients with schizophrenia
96. Medical illness in patients with schizophrenia
97. Diabetic dyslipidemia
98. Long-term effects of fish oil on lipoprotein subfractions and low density lipoprotein size in non-insulin-dependent diabetic patients with hypertriglyceridemia
99. Disorders of lipoprotein metabolism
100. Nonpharmacologic treatment of hypertriglyceridemia: Focus on fish oils
101. The unique human receptor binding profile may be related to lack of weight gain with ziprasidone